Discovery of Novel Amino Acids (Analogues)-Substituted Thiophene[3,2-]pyrimidine Derivatives as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Design, Synthesis, and Biological Evaluation.

Inspired by our previous work on the modification of diarylpyrimidine-typed non-nucleoside reverse transcriptase inhibitors (NNRTIs) and the reported crystallographic studies, a series of novel amino acids (analogues)-substituted thiophene[3,2-]pyrimidine derivatives were designed and synthesized by targeting the solvent-exposed region of the NNRTI-binding pocket. The biological evaluation results showed that compound was the most active inhibitor, exhibiting moderate-to-excellent potency against HIV-1 wild-type (WT) and a panel of NNRTI-resistant strains, with EC values ranging from 0.042 μM to 7.530 μM. Of special note, exhibited the most potent activity against single-mutant strains (K103N and E138K), with EC values of 0.031 μM and 0.094 μM, being about 4.3-fold superior to EFV (EC = 0.132 μM) and 1.9-fold superior to NVP (EC = 0.181 μM), respectively. In addition, demonstrated lower cytotoxicity (CC = 27.9 μM) and higher selectivity index values. The HIV-1 reverse transcriptase (RT) inhibition assay was further performed to confirm their binding target. Moreover, preliminary structure-activity relationships (SARs) and molecular docking studies were also discussed in order to provide valuable insights for further structural optimizations. In summary, turned out to be a promising NNRTI lead compound for further investigations of treatments for HIV-1 infections.